04:53 AM EDT, 04/15/2026 (MT Newswires) -- Mesoblast (MESO) said late Tuesday it acquired an exclusive worldwide license to a chimeric antigen receptor technology platform for augmentation of therapeutic mesenchymal lineage stromal cell products.

The company obtained the global rights to the CAR-MSC intellectual property developed at Mayo Clinic by acquiring a startup.

Mesoblast said the move is expected to help it generate products with even greater potency for ulcerative colitis or Crohn's disease, along with other benefits.

The company's shares were up 3.4% in premarket activity Wednesday.